What is the most likely diagnosis and recommended treatment for a 35‑year‑old woman with a 4‑month history of intermittent facial erythema on the cheeks and no alcohol use?

Diagnosis and Treatment of Intermittent Facial Erythema

This 35-year-old woman most likely has rosacea, specifically presenting with persistent centrofacial erythema with periodic intensification, and should be treated with topical brimonidine or intense pulsed light (IPL) as first-line therapy for the erythema. 1

Diagnosis: Rosacea

The 4-month history of intermittent red cheeks in a 35-year-old woman is diagnostic of rosacea based on the following:

• Persistent centrofacial erythema associated with periodic intensification by potential trigger factors is independently diagnostic of rosacea and represents the minimum diagnostic feature required for diagnosis. 1

• The intermittent nature ("some days more red than others") fits the pattern of transient erythema superimposed on persistent background erythema, which is the essential component of rosacea. 2, 3

• The age (35 years) and female sex are typical, as rosacea affects up to 10% of the population, especially fair-skinned individuals aged 35-50, with women affected more often than men. 2

• Importantly, flushing/transient erythema alone is NOT diagnostic of rosacea (requires the persistent component), but when combined with the 4-month duration, this represents persistent erythema with periodic worsening. 1

First-Line Treatment Options

Based on the phenotype-led treatment algorithm from the Global Rosacea Consensus (ROSCO) panel, the following are first-line treatments specifically for persistent erythema: 1

Topical Therapy

• Brimonidine (topical α-adrenergic agonist) is the only FDA-approved treatment specifically for persistent facial erythema of rosacea and provides rapid improvement. 1, 3

• Topical oxymetazoline (another α-adrenergic agonist) demonstrates clinically meaningful improvement beginning at 1 hour after the first application. 4

Light-Based Therapy

• Intense pulsed light (IPL) is a first-line option for persistent erythema and provides more durable results than topical vasoconstrictors. 1

• Pulsed-dye laser (PDL) is also listed as first-line for transient erythema. 1

Systemic Therapy

• Oral doxycycline (40 mg modified-release formulation) is listed as first-line for persistent erythema, though it primarily targets inflammatory components. 1

• Beta blockers (oral) are listed as first-line for transient erythema/flushing. 1

Treatment Algorithm

For isolated persistent erythema without papules/pustules:

1. Start with topical brimonidine or oxymetazoline for immediate symptom control, as these provide rapid reduction in erythema within hours of application. 4, 3

2. Consider IPL or PDL for more durable improvement, particularly if the patient desires long-term reduction rather than daily topical application. 1

3. Add general skincare measures: SPF 30+ sunscreen, gentle cleansers, moisturizers, and trigger avoidance (sun exposure, hot beverages, spicy foods, temperature extremes). 1

Important Caveats

• Brimonidine can cause rebound erythema in some patients, typically occurring hours after application wears off. This is a known adverse effect that should be discussed upfront. 3

• If inflammatory papules or pustules develop, add topical azelaic acid, ivermectin, or metronidazole as first-line agents. 1

• Assess for ocular symptoms (burning, dryness, foreign body sensation), as ocular rosacea occurs in a subset of patients and may require ophthalmology referral. 1

• In darker skin types (phototypes V-VI), erythema may not be visible, and diagnosis relies more heavily on symptoms of burning/stinging and history of periodic worsening. 1

• The absence of alcohol use is irrelevant to the diagnosis, as rosacea is not caused by alcohol consumption, though alcohol can be a trigger factor for flushing in those already affected. 1